No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 8 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Tiziana Life Sciences Ltd (TLSA) stock was $1.11 as of Oct 6, 2026, 4:00 PM EDT, up 3.74% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -45.5% · 3-year avg +16.3%/yr · 5-year avg -5.4%/yr
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis.
Biotechnology · London
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.08
vs Estimate
$-0.08
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TLSA | $70.63M | $1.11 | +3.74% | -45.53% | -5.37% | N/A | N/A |
| 2GANX | $71.23M | $1.67 | -1.18% | -11.93% | -25.06% | N/A | vs TLSA |
| 3CSBR | $69.61M | $5.01 | +0.80% | -21.02% | -13.07% | +12.07% | vs TLSA |
| 4VRCA | $72.32M | $4.21 | -2.32% | -7.67% | -48.68% | N/A | vs TLSA |
| 5SPRO | $68.90M | $1.19 | +2.59% | -43.26% | -42.70% | N/A | vs TLSA |
| 6HYFT | $72.83M | $1.55 | +4.03% | -11.78% | -23.93% | N/A | vs TLSA |
forward FY estimate
N/A
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$8.02
+622.7% upside
Low
$7.02
Current
$1.11
High
$9.02
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| FY 2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
